Form 8-K · Current Report · Filed 2026-08-06
Zoetis Reports Second Quarter 2026 Results and Updates Full Year Guidance
Zoetis Inc. reported flat revenue of $2.5 billion and a slight decrease in net income for the second quarter of 2026. The company also revised its full-year 2026 guidance, lowering both revenue and adjusted net income expectations. The U.S. segment saw a decline in revenue, while the International segment experienced growth. Zoetis continues to face challenges in the Companion Animal market but remains focused on innovation and growth in Livestock and Diagnostics.
- Filer
- Zoetis Inc. ZTS · NYSE
- Filed
- Accession
- 0001555280-26-000038
- CIK
- 0001555280
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$74.39
Since filing
+0.0%
Latest close
$74.39
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ZTS reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, ZTS insiders reported 9 Form 4 transactions — net buying of $70K.
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Never miss another ZTS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.